Drug Development Partnerships
The Disease Era is now
Capture and understand human disease biology in vitro
The key to unlocking effective therapies for the unsolved diseases of our times is a deep understanding of human disease biology. To this end, MIMETAS aims to capture the essence of diseases in fit-for-purpose in vitro models. We are fully committed to reducing human disease complexity into functional and screenable assays.
In the Compound Era, access to phenotypically discovered compounds used to drive new drug development. In the Target Era, over the last 30 years, target discovery and compound screening took over. Today, we can combine phenotypic models with screening capabilities in a new Disease Era, where human disease biology is central.
Partner with us
MIMETAS takes pride in being a trusted partner for innovative pharmaceutical companies in drug development trajectories. Our unique disease modeling capabilities, robust assays, and proprietary OrganoPlate platform create the core of our contribution. We stand shoulder-to-shoulder to understand disease mechanisms better. We do this by exploiting disease-relevant assays for screening of new targets and compounds followed by the selection of candidates, and further validation, all based on our phenotypic human models.
For more information about these partnerships, please get in touch with us.